Alnylam Pharmaceuticals, Inc. ALNY NASDAQ

Alnylam Pharmaceuticals, Inc. (ALNY) generated $524.08M in operating cash flow for fiscal year 2025. After capital expenditures of $58.7M, free cash flow was $465.38M.

Free cash flow margin was 12.5% of revenue. Cash conversion ratio was 1.67x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (76/100, Pass) — $465.38M (12.5% FCF margin) supports a durable competitive advantage
• INCOME (45/100) — Cash conversion ratio was 1.67x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 60/100 with 3/7 criteria passed.